Free Trial

Xenetic Biosciences (XBIO) Competitors

Xenetic Biosciences logo
$3.65 -0.05 (-1.35%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$3.58 -0.07 (-2.05%)
As of 07/7/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XBIO vs. VYNE, FGEN, RLMD, NAII, DRRX, VVOS, BLRX, BIVI, LPCN, and MTEX

Should you be buying Xenetic Biosciences stock or one of its competitors? The main competitors of Xenetic Biosciences include VYNE Therapeutics (VYNE), FibroGen (FGEN), Relmada Therapeutics (RLMD), Natural Alternatives International (NAII), DURECT (DRRX), Vivos Therapeutics (VVOS), BioLineRx (BLRX), BioVie (BIVI), Lipocine (LPCN), and Mannatech (MTEX). These companies are all part of the "med - drugs" industry.

Xenetic Biosciences vs. Its Competitors

VYNE Therapeutics (NASDAQ:VYNE) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

VYNE Therapeutics has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500.

In the previous week, VYNE Therapeutics had 3 more articles in the media than Xenetic Biosciences. MarketBeat recorded 3 mentions for VYNE Therapeutics and 0 mentions for Xenetic Biosciences. VYNE Therapeutics' average media sentiment score of 1.04 beat Xenetic Biosciences' score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
VYNE Therapeutics Positive
Xenetic Biosciences Neutral

VYNE Therapeutics presently has a consensus target price of $6.25, suggesting a potential upside of 384.50%. Given VYNE Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe VYNE Therapeutics is more favorable than Xenetic Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VYNE Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Xenetic Biosciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Xenetic Biosciences has higher revenue and earnings than VYNE Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VYNE Therapeutics$500K39.24-$39.83M-$0.99-1.30
Xenetic Biosciences$2.50M2.25-$3.96M-$2.38-1.53

Xenetic Biosciences has a net margin of -142.10% compared to VYNE Therapeutics' net margin of -6,974.55%. Xenetic Biosciences' return on equity of -57.31% beat VYNE Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
VYNE Therapeutics-6,974.55% -71.89% -58.94%
Xenetic Biosciences -142.10%-57.31%-49.30%

83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 4.8% of VYNE Therapeutics shares are held by company insiders. Comparatively, 14.7% of Xenetic Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

VYNE Therapeutics beats Xenetic Biosciences on 9 of the 16 factors compared between the two stocks.

Get Xenetic Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XBIO vs. The Competition

MetricXenetic BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.71M$2.43B$5.52B$9.02B
Dividend YieldN/A1.78%5.24%4.08%
P/E Ratio-1.538.7527.1920.04
Price / Sales2.25473.55395.22100.83
Price / CashN/A21.7726.2128.59
Price / Book0.944.497.925.55
Net Income-$3.96M$31.26M$3.17B$248.49M
7 Day Performance-2.67%1.27%1.79%4.87%
1 Month Performance18.70%2.46%1.28%6.63%
1 Year Performance-16.67%-0.29%33.32%20.38%

Xenetic Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XBIO
Xenetic Biosciences
0.5924 of 5 stars
$3.65
-1.4%
N/A-9.0%$5.71M$2.50M-1.534Gap Down
VYNE
VYNE Therapeutics
3.0479 of 5 stars
$1.65
+16.2%
$6.25
+278.8%
-29.9%$21.60M$500K-1.6730News Coverage
Positive News
High Trading Volume
FGEN
FibroGen
4.7005 of 5 stars
$5.30
+1.5%
$250.00
+4,617.0%
-70.2%$21.10M$29.62M-2.12570Positive News
RLMD
Relmada Therapeutics
4.5971 of 5 stars
$0.60
-1.6%
$5.00
+732.9%
-79.8%$20.25MN/A-0.2410Gap Down
NAII
Natural Alternatives International
1.0026 of 5 stars
$3.28
+1.9%
N/A-40.1%$19.90M$113.80M-2.36290
DRRX
DURECT
0.5335 of 5 stars
$0.64
+1.4%
N/A-51.1%$19.44M$2.03M-4.2380Gap Down
VVOS
Vivos Therapeutics
0.7569 of 5 stars
$3.16
-3.7%
$4.82
+52.4%
+124.8%$19.32M$15.03M-1.83160
BLRX
BioLineRx
2.6952 of 5 stars
$4.57
+3.2%
$26.00
+468.9%
-80.2%$18.88M$28.94M-0.5240
BIVI
BioVie
0.3661 of 5 stars
$0.93
-8.4%
N/A+98.0%$18.76MN/A-0.1210
LPCN
Lipocine
1.5662 of 5 stars
$3.16
-4.0%
$9.00
+184.8%
-57.3%$17.60M$11.20M-3.1010
MTEX
Mannatech
0.2714 of 5 stars
$9.35
+3.9%
N/A+20.4%$17.11M$117.87M-93.50250High Trading Volume

Related Companies and Tools


This page (NASDAQ:XBIO) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners